Treatment Registry
TR-0125 ActiveRecorded September 2, 2026Last verified September 3, 2026

Brand tirzepatide

Sold by Hers · Injection, pen · every brand tirzepatide record

What you actually pay

Per month

$448

Medication · Zepbound KwikPen$299
Required membership$149

Added from the figures recorded below.

Price

TermPer monthCharged today
Zepbound KwikPen

Zepbound ® KwikPen ® From $299/mo †

source, read September 2, 2026

Per month$299Charged today$299
Visit Hers

We earn nothing from this link. Hers has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

History

  1. September 2, 2026$299
  2. September 3, 2026$299
  • September 2, 2026Entry added to the register

Sourcing and terms

PharmacyApostrophe Pharmacy LLC; XeCare LLC; EHT Pharmacy LLC dba Curexa; CD Pharmacy LLC dba Red Rock Pharmacy; AnazaoHealth Corporation; Strive Specialties, Inc.
StatesNot disclosed
PrescriberBoth
Cancellation“You can cancel anytime, but canceling your membership will also cancel any active medication plan and access to care through the platform.”
MembershipRequired. $149 per month. “An active Hers Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership.”

Not yet checked: consult fee.

Recorded from forhers.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2, 2026Foundayo (orforglipron, $149/mo) is also sold here but doesn't match any of this register's six `drug` values (not semaglutide/tirzepatide/liraglutide), so it is omitted from `entries` rather than misclassified. Zepbound and Mounjaro also appear at a flat $1,899/mo with no dose or form stated, alongside the dose-based $299/mo Zepbound Vial/KwikPen listings just above them — the page never explains why the $1,899 figures are so much higher; possibly an un-discounted list price shown without qualification.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0125
Readings
2

Related records

What else Hers sells

All Hers programs and terms

Brand tirzepatide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 59 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Hers brand tirzepatide (TR-0125). Last verified September 3, 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0125

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.